Sentence examples for for future cost effectiveness from inspiring English sources
To our knowledge, the comparative cost effectiveness of simplified human papillomavirus test based strategies compared with extended test protocols has not been examined in these settings and is a potential subject for future cost effectiveness analyses.
Finally, our model provides the foundation for future cost-effectiveness analyses to evaluate targeted screening and various management strategies for EAC, a pressing clinical and policy issue as there is currently no accepted strategy.
Costs per life year gained were computed to enhance applicability for future cost-effectiveness analysis (CEA).
In combination with a costing study, the health outcome data provide the basis for future cost-effectiveness and cost-benefit analyses.
Including the community cost of a relapse provides a more realistic figure for future cost-effectiveness analysis of adjuvant breast cancer therapies.
The results of our study may be useful in advising patients and providers regarding expected outcomes of the various HGD management strategies as well as providing utility scores for future cost-effectiveness analyses.
Our results provide information that is relevant to decision-making and that might prove necessary for future cost-effectiveness studies comparing current oral anticoagulation drugs with newly developed drugs.
Furthermore, combined with further data related to average duration of a clinical episode and the frequency of recurrence of GW, the detailed utilities findings from the current study would be informative for future cost-effectiveness evaluations related to quality-adjusted life years saved by new interventions against GW.
The EQ-5D utility scores from this study provide a preference-based score that can be used to calculate quality-adjusted life years for future cost-effectiveness analyses of treatment or prevention of diabetes and evaluating healthcare interventions both clinically and economically.
Our findings suggest that scores based on the Japanese preference weights could be regarded as the baseline utility values for future cost-effectiveness evaluations, whilst the results based on the UK and US populations could provide a plausible range of utilities estimates for sensitivity analysis.
A mapping function can be used to estimate EQ-5D-3L from (combined) early trial data for planning future cost-effectiveness argument for a phase III trial.
